Skip to main content

Table 4 Association of the ACE gene D/I polymorphism, without CFTR genotype distribution and presence of B. cepacia (BC)

From: The ACE gene D/I polymorphism as a modulator of severity of cystic fibrosis

Group Ace genotype Presence Absence Total X2 p X2 p OR (CI 5-95%)
Without taking CFTR mutation into account I/I 8 64 72 8.654 0.013 0.468 0.498 0.699 (0.319 – 1.534)
I/D 9 74 82 0.814 0.182 0.651 (0.304 – 1.394)
D/D 8 16 24 8,653 0.003 4.509 (1.513 – 10.89)
No identified CFTR mutation I/I 3 18 21 0.530 0.767 0.003 1.29 1.056 (0.188 - 5.925)
I/D 2 16 18 0.204 1.00 0.656 (0.107 - 4.041)
D/D 1 3 4 0.438 0.93 2.267 (0.196 - 26.27)
One CFTR mutation identified class I, II or III I/I 2 20 22 5.539 0.063 1.248 0.466 0.383 (0.069 - 2.117)
I/D 2 18 20 0.787 0.629 0.463 (0.084 - 2.562)
D/D 4 5 9 6.834 0.027 7.6 (1.43 - 40.38)
Two CFTR mutation identified class I, II or III I/I 3 26 29 0.511 0.774 0.084 1.07 0.8077 (0.193 - 3.387)
I/D 5 40 45 0.039 1.10 0.875 (0.234 - 3.275)
D/D 2 9 11 0.495 0.764 1.833 (0.335 - 10.02)
  1. Values below 0.05 for p denote clinical correlation between variables. OR - odds ratio, CI- confidence interval, D - deleted allele, I - insertion allele. No identified mutation (44 patients) – patients without of identified mutation in classes I, II or III. One identified mutation (51 patients) – patient with one identified mutation in class I, II, or III. Two identified mutation (85 patients) – patient with two mutations in class I, II or III.